Clinical Trial

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-09.
Trial Details
NCT Number NCT07333183
Lead Sponsor Pulmovant, Inc.
Conditions Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Enrollment 20 participants
Start Date 2025-12-23
Primary Completion 2026-12 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-22